{"id":"busulphan","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Anemia","Bacterial infectious disease","Breastfeeding (mother)","Epilepsy","Fanconi's anemia","Fibrosis of lung","Hyperglycemia","Hyperuricemia","Hypokalemia","Hypomagnesemia","Mycosis","Neutropenic disorder","Portal vein obstruction","Pregnancy, function","Radiation oncology AND/OR radiotherapy","Severe Bone Marrow Depression","Thrombocytopenic disorder","Viral disease"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01800643","NCT01141543","NCT01370408","NCT03079089","NCT00002547","NCT00304018","NCT00416598","NCT01814475","NCT02579967","NCT02512497","NCT00785330","NCT00623935","NCT00024050","NCT01572662","NCT05735717","NCT00004231","NCT03384212","NCT00030719","NCT02582775","NCT07500753","NCT01071239","NCT02906202","NCT02759822","NCT03922724","NCT01779882","NCT01666080","NCT01814488","NCT00003462","NCT05510505","NCT03583294","NCT00004899","NCT00852163","NCT01279616","NCT00809276","NCT00731328","NCT01565616","NCT00002831","NCT00596154","NCT04713956","NCT03509961","NCT03337568","NCT01413178","NCT06001385","NCT00598481","NCT01916252","NCT03792815","NCT06207799","NCT01118013","NCT01496547","NCT00070174"],"aliases":["Busulfan","Bulsivex"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Busulphan","companyId":"university-of-birmingham","ecosystem":[],"mechanism":{"target":"Matrix metalloproteinase-9","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"University of Birmingham","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Busulphan","indications":{"approved":[{"name":"Allogeneic bone marrow transplantation","diseaseId":"allogeneic-bone-marrow-transplantation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","diseaseId":"autologous-hematopoietic-stem-cell-transplantation-for-ewing's-sarcoma-family-of-tumors","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malignant lymphoma","diseaseId":"malignant-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neuroblastoma","diseaseId":"neuroblastoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","diseaseId":"philadelphia-chromosome-positive-chronic-myelocytic-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01800643","phase":"Phase 2","title":"Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Hospital Israelita Albert Einstein","isPivotal":true,"enrollment":100,"indication":"Acute Leukemia, Chronic Leukemia","completionDate":"2014-12"},{"nctId":"NCT01141543","phase":"N/A","title":"Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients With AML Undergoing Allografting: Assessment of Feasibility and Efficacy","status":"COMPLETED","sponsor":"University Health Network, Toronto","isPivotal":false,"enrollment":12,"indication":"Acute Myeloid Leukemia","completionDate":"2014-05"},{"nctId":"NCT01370408","phase":"Phase 2","title":"A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","isPivotal":false,"enrollment":85,"indication":"Chemotherapy-induced Nausea and Vomiting","completionDate":"2016-03"},{"nctId":"NCT03079089","phase":"NA","title":"Sequential Chemotherapy Prior Conditioning Reduced Intensity: Study Routine Care in Haploidentical Allogeneic Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Di","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","isPivotal":false,"enrollment":40,"indication":"Refractory or Relapsed Lymphoid Haemopathy","completionDate":"2023-09-11"},{"nctId":"NCT00002547","phase":"Phase 2","title":"ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","isPivotal":false,"enrollment":280,"indication":"Leukemia, Myelodysplastic Syndromes","completionDate":"2003-10"},{"nctId":"NCT00304018","phase":"Phase 1","title":"Pilot Study of Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":5,"indication":"Leukemia, Lymphoma","completionDate":"2009-03"},{"nctId":"NCT00416598","phase":"Phase 2","title":"Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML < 60 Years","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":546,"indication":"Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes","completionDate":"2016-12-01"},{"nctId":"NCT01814475","phase":"Phase 2","title":"Prospective, Phase II Randomized Study to Compare Busulfan-fludarabine Reduced-intensity Conditioning (RIC) With Thiotepa-fludarabine RIC Regimen Prior to Allogeneic Transplantation of Hematopoietic C","status":"COMPLETED","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","isPivotal":false,"enrollment":62,"indication":"Myelofibrosis","completionDate":"2016-12-31"},{"nctId":"NCT02579967","phase":"Phase 2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":354,"indication":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency","completionDate":"2036-12-31"},{"nctId":"NCT02512497","phase":"Phase 1","title":"Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","isPivotal":false,"enrollment":23,"indication":"Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia","completionDate":"2025-06-18"},{"nctId":"NCT00785330","phase":"Phase 2","title":"Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-prophylaxis With or Without Rituximab in Pati","status":"COMPLETED","sponsor":"Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH","isPivotal":false,"enrollment":84,"indication":"Non-Hodgkin's Lymphoma","completionDate":"2011-04"},{"nctId":"NCT00623935","phase":"Phase 2","title":"Hematopoietic Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","isPivotal":false,"enrollment":56,"indication":"Acute Myelogenous Leukemia","completionDate":"2015-11"},{"nctId":"NCT00024050","phase":"Phase 2","title":"Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for the Treatment of \"Less Advanced\" Myelodysplasi","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":0,"indication":"Leukemia, Myelodysplastic Syndromes","completionDate":"2007-08"},{"nctId":"NCT01572662","phase":"Phase 2","title":"Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":201,"indication":"Leukemia, Acute Myeloid Leukemia","completionDate":"2022-08-11"},{"nctId":"NCT05735717","phase":"Phase 2","title":"Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","isPivotal":false,"enrollment":70,"indication":"Hematologic Malignancy, Acute Leukemia","completionDate":"2030-11-30"},{"nctId":"NCT00004231","phase":"Phase 2","title":"Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":0,"indication":"Lymphoma","completionDate":"2006-08"},{"nctId":"NCT03384212","phase":"Phase 3","title":"CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","isPivotal":true,"enrollment":120,"indication":"High Risk Acute Myeloid Leukemia, Allogeneic Hematopoeitic Stem Cell Transplantation","completionDate":"2022-07-31"},{"nctId":"NCT00030719","phase":"Phase 3","title":"High Risk Neuroblastoma Study 1 Of Siop-Europe","status":"UNKNOWN","sponsor":"University of Leicester","isPivotal":true,"enrollment":175,"indication":"Neuroblastoma","completionDate":""},{"nctId":"NCT02582775","phase":"Phase 2","title":"MT2015-20: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Cell Transplantation and Serial Donor Mesenchymal Cell Infusions","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","isPivotal":false,"enrollment":17,"indication":"Epidermolysis Bullosa","completionDate":"2023-07-26"},{"nctId":"NCT07500753","phase":"NA","title":"A Single-arm, Prospective Study of a Cladribine-Bridged Lisaftolax and Busulfan Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Myelodysplastic Syndr","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","isPivotal":false,"enrollment":30,"indication":"Relapsed or Refractory Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)","completionDate":"2029-06-30"},{"nctId":"NCT01071239","phase":"Phase 2","title":"A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busu","status":"COMPLETED","sponsor":"Medical College of Wisconsin","isPivotal":false,"enrollment":1,"indication":"Fanconi Anemia","completionDate":"2016-08-30"},{"nctId":"NCT02906202","phase":"Phase 3","title":"A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype, by Transplantation of Autologous C","status":"COMPLETED","sponsor":"Genetix Biotherapeutics Inc.","isPivotal":true,"enrollment":24,"indication":"Beta-Thalassemia","completionDate":"2022-03-31"},{"nctId":"NCT02759822","phase":"N/A","title":"Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias","status":"UNKNOWN","sponsor":"Leonardo Javier Arcuri","isPivotal":false,"enrollment":30,"indication":"Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma","completionDate":""},{"nctId":"NCT03922724","phase":"Phase 2","title":"Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":330,"indication":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders","completionDate":"2030-10-31"},{"nctId":"NCT01779882","phase":"NA","title":"Cyclophosphamide-Busulfan Versus Busulfan-Cyclophosphamide as Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: a Prospective Randomized Study to Assess Live","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","isPivotal":false,"enrollment":72,"indication":"Myeloid Leukemia, Precursor Myeloid Neoplasms","completionDate":"2018-01-06"},{"nctId":"NCT01666080","phase":"NA","title":"Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","isPivotal":false,"enrollment":30,"indication":"Hematologic Disorders, Hemoglobinopathies","completionDate":"2027-06"},{"nctId":"NCT01814488","phase":"Phase 2","title":"A Phase II Multicentre Open-label Study on Allogeneic Stem Cell Transplantation From Unrelated, Cord-blood and Family Haploidentical Donors in Patients With Active Acute Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","isPivotal":false,"enrollment":101,"indication":"Acute Leukemia","completionDate":"2017-06-30"},{"nctId":"NCT00003462","phase":"Phase 1","title":"Phase I Study of Intrathecal Spartaject-Busulfan in Patients With Neoplastic Meningitis","status":"COMPLETED","sponsor":"Duke University","isPivotal":false,"enrollment":20,"indication":"Brain and Central Nervous System Tumors","completionDate":"2001-02"},{"nctId":"NCT05510505","phase":"Phase 2","title":"A Prospective, Randomized, Multi-center Study to Assess the Efficacy and Safety of GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in Severe Aplastic Anemia Patien","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","isPivotal":false,"enrollment":100,"indication":"Aplastic Anemia","completionDate":"2025-12"},{"nctId":"NCT03583294","phase":"NA","title":"A Study on the Uterus, Ovarian and Reproductive Functions According to Conditioning Regimen and Pubertal Status at the Time of Stem Cell Transplantation in a Leukemia Pediatric Population","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","isPivotal":false,"enrollment":212,"indication":"Leukemia","completionDate":"2021-04-01"},{"nctId":"NCT00004899","phase":"Phase 2","title":"Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":0,"indication":"Leukemia, Myelodysplastic Syndromes","completionDate":"2004-08"},{"nctId":"NCT00852163","phase":"Phase 2","title":"Phase II Trial of Clofarabine With Parenteral Busulfan (Busulfex®) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases","status":"COMPLETED","sponsor":"Baylor Research Institute","isPivotal":false,"enrollment":20,"indication":"Leukemia, Myelodysplastic Syndrome","completionDate":"2011-12"},{"nctId":"NCT01279616","phase":"Phase 2","title":"A Pilot Study of an Immunosuppressive and Myeloablative Preparative Regimen for Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) for Severe Sickle Cell Disease","status":"TERMINATED","sponsor":"Nationwide Children's Hospital","isPivotal":false,"enrollment":8,"indication":"Sickle Cell Disease","completionDate":"2015-01"},{"nctId":"NCT00809276","phase":"Phase 1","title":"Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosup","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":92,"indication":"Lymphoma, Multiple Myeloma","completionDate":"2011-12"},{"nctId":"NCT00731328","phase":"Phase 2","title":"HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SY","status":"COMPLETED","sponsor":"Asan Medical Center","isPivotal":false,"enrollment":15,"indication":"Leukemia, Myelodysplastic Syndromes","completionDate":"2013-12"},{"nctId":"NCT01565616","phase":"Phase 2","title":"A Phase II Study of Hematopoietic Stem Cell Therapy for Young Adults With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Emory University","isPivotal":false,"enrollment":22,"indication":"Sickle Cell Disease","completionDate":"2016-06-30"},{"nctId":"NCT00002831","phase":"Phase 1","title":"A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":24,"indication":"Leukemia","completionDate":"2002-12-31"},{"nctId":"NCT00596154","phase":"Phase 2","title":"Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":33,"indication":"CNS Lymphoma, CNS Brain Cancer","completionDate":"2023-02-02"},{"nctId":"NCT04713956","phase":"Phase 2","title":"G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","isPivotal":true,"enrollment":242,"indication":"Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation","completionDate":"2024-07-31"},{"nctId":"NCT03509961","phase":"Phase 2","title":"A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic H","status":"RECRUITING","sponsor":"Pediatric Transplantation & Cellular Therapy Consortium","isPivotal":false,"enrollment":95,"indication":"B-cell Acute Lymphoblastic Leukemia","completionDate":"2026-07-01"},{"nctId":"NCT03337568","phase":"N/A","title":"Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML","status":"UNKNOWN","sponsor":"Asan Medical Center","isPivotal":false,"enrollment":110,"indication":"Acute Myeloid Leukemia","completionDate":"2021-03-30"},{"nctId":"NCT01413178","phase":"Phase 3","title":"A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":true,"enrollment":205,"indication":"Myeloma","completionDate":"2019-03-10"},{"nctId":"NCT06001385","phase":"Phase 2","title":"A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Ste","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","isPivotal":false,"enrollment":313,"indication":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","completionDate":"2026-06-30"},{"nctId":"NCT00598481","phase":"Phase 2","title":"ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID","status":"COMPLETED","sponsor":"Fondazione Telethon","isPivotal":false,"enrollment":12,"indication":"Immunologic Deficiency Syndromes","completionDate":"2019-06-19"},{"nctId":"NCT01916252","phase":"Phase 3","title":"A Randomized, National, Open-label, Multicenter, Phase III Trial Studying Induction Therapy With Bortezomib/Lenalidomide/Dexamethasone (VRD-GEM), Followed by High-dose Chemotherapy With Melphalan-200 ","status":"COMPLETED","sponsor":"PETHEMA Foundation","isPivotal":true,"enrollment":460,"indication":"Multiple Myeloma","completionDate":"2016-11-16"},{"nctId":"NCT03792815","phase":"Phase 2","title":"Open-labelled, Multicenter Phase II Clinical Trial of Intravenous Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation in Patients With Poor-risk, Refractory or Relapsed No","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","isPivotal":false,"enrollment":51,"indication":"Non-Hodgkin's Lymphoma","completionDate":"2013-09"},{"nctId":"NCT06207799","phase":"Phase 2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":40,"indication":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy","completionDate":"2031-12-31"},{"nctId":"NCT01118013","phase":"Phase 2","title":"Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","isPivotal":false,"enrollment":6,"indication":"Leukemia, Lymphoma","completionDate":"2013-08"},{"nctId":"NCT01496547","phase":"Phase 2","title":"Sequential Intensive Chemotherapy Followed by Allogeneic Stem Cell Transplantation With Reduce-intensity Conditioning for Refractory and Relapse Acute Myeloid Leukemia in Adult Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","isPivotal":false,"enrollment":47,"indication":"Acute Leukemia","completionDate":"2018-06-30"},{"nctId":"NCT00070174","phase":"Phase 2","title":"Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study","status":"COMPLETED","sponsor":"Children's Oncology Group","isPivotal":false,"enrollment":350,"indication":"Leukemia","completionDate":"2013-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":61,"withResults":9},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}